Uncategorized

More problems for Abbott, Score One for Dexcom

This morning Dexcom (NASDAQ:DXCM) said a Delaware court has granted a stay in the patent infringement case filed against it by Abbott (NYSE:ABT). The court also dismissed a claim filed by Abbott seeking to add three additional patents to the lawsuit. Undeterred Abbott has filed a separate action in the same court alleging infringement of three patents mentioned in the amendment. Abbott is still waiting for the Food...

Amylin – Some good news

After a series of downgrades by some analysts Amylin (NASDAQ:AMLN) had some good news today when they announced that the Byetta cartridge issue has been resolved. As we indicated previously investors would be wise to add to their Amylin holdings should shares show any signs of weakness. Diabetic Investor sees no reason to alter our view and sees the window of opportunity closing quickly. We also find it interesting...

Update

Just as a reminder I will be attending the American Association of Diabetes Educators Conference in LA this week and will back in the office next Monday August 14th. I will be reachable on my mobile number and will also have access to email. If you are going to be attending the AADE and would like to meet, contact me and I’ll do my best to accommodate your request. David...

Update

Just as a reminder I will be attending the American Association of Diabetes Educators Conference in LA this week and will back in the office next Monday August 14th. I will be reachable on my mobile number and will also have access to email. If you are going to be attending the AADE and would like to meet, contact me and I’ll do my best to accommodate your request. David...

Nektar Results

This afternoon after the market closed Nektar Therapeutics (NASDAQ:NKTR) released 2006 second quarter results. During the quarter product sales and royalty revenue was $44.2, this includes three months of Exubera product sales to Pfizer (NYSE:PFE). Scheduled to be launched next month Exubera is the first inhaled insulin product to be approved by the Food and Drug Administration (FDA). For the full year 2006 the company expects $70 to $90 million...

MannKind – Will They Make it to the Finish Line

This morning MannKind Corporation (NASDAQ:MNKD) reported second quarter results which appeared to indicate the company is having trouble finding a strategic partner and may be in danger of running out of cash. The company announced that they had entered into a loan agreement with company founder Al Mann to borrow up to $150 million and has already accessed $50 million of this amount. During this mornings conference call the...

Novo Sues Pfizer

This morning Novo Nordisk (NYSE:NVO) announced results for the first six months of 2006 which included a surprise, the company has filed a patent infringement lawsuit against Pfizer (NYSE:PFE) over their inhaled insulin product Exubera. Pfizer had previously announced they were planning on launching Exubera in the United States next month. According to Jim Shehan, general counsel for Novo Nordisk, “We’re trying to protect our intellectual property. We’ve been a...

Amylin Reports and more problems for Abbott

Yesterday afternoon Amylin Pharmaceuticals (NASDAQ:AMLN) announced their 2006 second quarter results. According to the company revenues hit $118.1 million in the quarter, with net product sales of $108.8 million. Byetta hit $98.6 million in sales while Symlin achieved $10.2 million in sales, both numbers beating Street estimates. As much as Diabetic Investor would like to gloat over these results and Amylin’s continued march towards $50 per share and beyond, we...

Buying Opportunity Amylin

This morning Amylin Pharmaceuticals (NASDAQ:AMLN) announced unaudited net product sales for Byetta® for the quarter ended June 30, 2006 were $98.6 million, far surpassing consensus Street estimates of $87.8 million. These strong sales numbers are somewhat surprising given the temporary supply issues with the cartridges for Byetta pens, which caused the company to dampen demand for the product. Lehman Brothers promptly downgraded the stock on the news which has caused...

Exubera Update, Roche Reports

This morning Pfizer (NYSE:PFE) provided an updated status for the launch of their inhaled insulin product Exubera. Here’s what we learned today: A. A. Physician and patient education will begin July 24, 2006 and be rolled out in phases. B. B. Initial supplies of Exubera will be available in September. C. C. Starter kits that will be used in the education phase should be available...